Details of Disease

General Information of Disease (ID: DIS8IZVM)

Disease Name	Liposarcoma
Synonyms	lip sarcoma; liposarcoma, malignant; liposarcoma; sarcoma of lip
Disease Class	2B59: Liposarcoma
Definition	A usually painless malignant tumor that arises from adipose tissue. Microscopically, it may contain a spectrum of neoplastic adipocytes ranging from lipoblasts to pleomorphic malignant adipocytes. Morphologic variants include: well differentiated, dedifferentiated, pleomorphic, and myxoid liposarcoma. The metastatic potential is higher in less differentiated tumors.
Disease Hierarchy	DISWU5AU: Lipomatous cancer DISSN8XB: Soft tissue sarcoma DISZDG3U: Sarcoma DIS8IZVM: Liposarcoma
ICD Code	ICD-11 ICD-11: 2B59
Disease Identifiers	MONDO ID MONDO_0005060 UMLS CUI C0023827 MedGen ID 44177 HPO ID HP:0012034 Orphanet ID 69078 SNOMED CT ID 1162815008

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Eribulin	DM1DX4Q	Approved	Small molecular drug	[1]
Trabectedin	DMG3Y89	Approved	Small molecular drug	[2]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Milademetan	DMPVDQ3	Phase 3	Small molecule	[3]
Selinexor	DMBD4K3	Phase 3	Small molecular drug	[4]
HDM201	DMVRTCW	Phase 1	NA	[4]
PF-07220060	DMPKO84	Phase 1	NA	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 23 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CD6	TTMF6KC	Limited	Genetic Variation	[6]
FUS	TTKGYZ9	Limited	Biomarker	[7]
HMBS	TTT0HW3	Limited	Biomarker	[8]
HMGA2	TTSTVM0	Limited	Altered Expression	[9]
MAZ	TT059DA	Limited	Altered Expression	[10]
MDM2	TT9TE0O	Limited	Biomarker	[11]
ATP2A2	TTE6THL	moderate	Altered Expression	[12]
DYRK1B	TTYGQ8A	moderate	Biomarker	[13]
CASP10	TTX5HEK	Strong	Biomarker	[14]
CDK11B	TT5Q79O	Strong	Biomarker	[15]
CDK19	TTNABU9	Strong	Biomarker	[15]
CDK4	TT0PG8F	Strong	Genetic Variation	[16]
CPM	TTVOH2M	Strong	Genetic Variation	[17]
CTAG1A	TTE5ITK	Strong	Altered Expression	[18]
DDR2	TTU98HG	Strong	Biomarker	[19]
EML4	TT92GY4	Strong	Genetic Variation	[20]
FASN	TT7AOUD	Strong	Therapeutic	[21]
FOLH1	TT9G4N0	Strong	Biomarker	[22]
HMGB2	TTA78JQ	Strong	Genetic Variation	[6]
PLIN1	TTIV27N	Strong	Altered Expression	[23]
PNPLA3	TTEUAEH	Strong	Altered Expression	[24]
SREBF1	TTER0UB	Strong	Biomarker	[25]
TARDBP	TT9RZ03	Strong	Biomarker	[26]
------------------------------------------------------------------------------------


⏷ Show the Full List of 23 DTT(s)

This Disease Is Related to 1 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
MSRA	DEU2ZBY	moderate	Biomarker	[27]
------------------------------------------------------------------------------------

This Disease Is Related to 47 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
GPS2	OT065FSS	Limited	Biomarker	[28]
PRUNE1	OTQ3UHWQ	Limited	Biomarker	[29]
SPIN1	OT69VAOX	Limited	Biomarker	[10]
TRIO	OT71X1AK	Limited	Biomarker	[30]
CAVIN2	OTFHHDRU	moderate	Altered Expression	[31]
CCDC180	OT4AL3LW	moderate	Biomarker	[32]
E2F4	OTB3JFH4	moderate	Altered Expression	[33]
G0S2	OT8FL49L	moderate	Altered Expression	[34]
HEATR3	OTB52FZ4	moderate	Biomarker	[35]
OSBP	OT7R0OQQ	moderate	Biomarker	[36]
SBF1	OTW6I9RV	moderate	Biomarker	[36]
SOX21	OTNT50CC	moderate	Biomarker	[37]
TP53INP2	OT0GTBXO	moderate	Altered Expression	[38]
CAPN3	OTCHG3YK	Strong	Biomarker	[39]
CAVIN1	OTFO915U	Strong	Biomarker	[40]
CENPV	OTPQ0KT9	Strong	Biomarker	[41]
CRISPLD2	OTVSFHTL	Strong	Altered Expression	[42]
CTAG1B	OTIQGW6U	Strong	Altered Expression	[18]
DNM3	OTDMUGCR	Strong	Biomarker	[43]
EIF2S1	OTM0GDTP	Strong	Biomarker	[41]
EIF2S2	OTXF0B09	Strong	Biomarker	[41]
EIF2S3	OTARRES9	Strong	Biomarker	[41]
EWSR1	OT7SRHV3	Strong	Biomarker	[44]
FRS2	OTDMD800	Strong	Biomarker	[45]
HCCS	OTQE88BE	Strong	Biomarker	[46]
HOXC13	OT52AVNA	Strong	Altered Expression	[47]
IFI44	OTOKSZVA	Strong	Genetic Variation	[6]
IGF2BP2	OT4ZSEEE	Strong	Altered Expression	[48]
IMMP2L	OT9WGAFD	Strong	Altered Expression	[48]
MBTPS2	OT67CC7W	Strong	Altered Expression	[49]
MEPE	OTXJRUW0	Strong	Biomarker	[50]
MYOCD	OTSJNHTH	Strong	Altered Expression	[51]
NAB2	OTG4BDF3	Strong	Biomarker	[52]
NANS	OTMQ2FUH	Strong	Genetic Variation	[53]
NF1	OTC29NHH	Strong	Genetic Variation	[54]
PNPLA2	OTR3ERMR	Strong	Biomarker	[34]
PSMD8	OTY6X27P	Strong	Altered Expression	[55]
RASA2	OTL06RG2	Strong	Biomarker	[20]
RPS14	OTB90KV5	Strong	Altered Expression	[55]
SPPL3	OT2HLJF6	Strong	Altered Expression	[48]
TAB2	OTPZK76F	Strong	Altered Expression	[56]
TAF12	OTQZII5O	Strong	Altered Expression	[44]
TAF15	OTNE038N	Strong	Altered Expression	[44]
TCN1	OTW6A49Y	Strong	Altered Expression	[6]
THRSP	OTKYE01L	Strong	Altered Expression	[55]
TSN	OTOFAQ2Z	Strong	Biomarker	[57]
TSPAN31	OT8WQ83R	Strong	Genetic Variation	[53]
------------------------------------------------------------------------------------


⏷ Show the Full List of 47 DOT(s)

References

1	Eribulin FDA Label
2	Trabectedin FDA Label
3	ClinicalTrials.gov (NCT04979442) A Randomized Multicenter Phase 3 Study of Milademetan Versus Trabectedin in Patients With Dedifferentiated Liposarcoma. U.S.National Institutes of Health.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	ClinicalTrials.gov (NCT04557449) Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4). U.S. National Institutes of Health.
6	Expression of human papillomavirus type 16 E7 oncoprotein alters keratinocytes expression profile in response to tumor necrosis factor-alpha.Carcinogenesis. 2010 Mar;31(3):521-31. doi: 10.1093/carcin/bgp333. Epub 2009 Dec 30.
7	Bromodomain and extraterminal proteins foster the core transcriptional regulatory programs and confer vulnerability in liposarcoma.Nat Commun. 2019 Mar 22;10(1):1353. doi: 10.1038/s41467-019-09257-z.
8	Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets.Oncotarget. 2015 May 20;6(14):12234-47. doi: 10.18632/oncotarget.3498.
9	Let-7 microRNA and HMGA2 levels of expression are not inversely linked in adipocytic tumors: analysis of 56 lipomas and liposarcomas with molecular cytogenetic data.Genes Chromosomes Cancer. 2011 Jun;50(6):442-55. doi: 10.1002/gcc.20869. Epub 2011 Mar 15.
10	The histone code reader SPIN1 controls RET signaling in liposarcoma.Oncotarget. 2015 Mar 10;6(7):4773-89. doi: 10.18632/oncotarget.3000.
11	Perinephric myxoid pseudotumor of fat: a distinctive pseudoneoplasm most often associated with non-neoplastic renal disease.Hum Pathol. 2019 May;87:37-43. doi: 10.1016/j.humpath.2019.02.005. Epub 2019 Mar 1.
12	Preferential cytotoxicity of bortezomib toward highly malignant human liposarcoma cells via suppression of MDR1 expression and function. Toxicol Appl Pharmacol. 2015 Feb 15;283(1):1-8. doi: 10.1016/j.taap.2014.12.015. Epub 2015 Jan 6.
13	Targeting DYRK1B suppresses the proliferation and migration of liposarcoma cells.Oncotarget. 2017 Nov 28;9(17):13154-13166. doi: 10.18632/oncotarget.22743. eCollection 2018 Mar 2.
14	Involvement of c-jun in human liposarcoma growth: supporting data from clinical immunohistochemistry and DNAzyme efficacy.Cancer Biol Ther. 2008 Aug;7(8):1297-301. doi: 10.4161/cbt.7.8.6301. Epub 2008 Aug 13.
15	Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells.Cancer Lett. 2014 Jan 1;342(1):104-12. doi: 10.1016/j.canlet.2013.08.040. Epub 2013 Sep 2.
16	Efficacy of a CDK4/6 Inhibitor in a Patient with Breast Cancer and Liposarcoma: A Case Report and Review of the Literature.Breast Care (Basel). 2019 Oct;14(5):325-328. doi: 10.1159/000493370. Epub 2018 Nov 14.
17	Liposarcomas of the mediastinum and thorax: a clinicopathologic and molecular cytogenetic study of 24 cases, emphasizing unusual and diverse histologic features.Am J Surg Pathol. 2012 Sep;36(9):1395-403. doi: 10.1097/PAS.0b013e3182562bc1.
18	Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma.Oncotarget. 2016 Nov 8;7(45):72860-72867. doi: 10.18632/oncotarget.12096.
19	Whole genome analyses of a well-differentiated liposarcoma reveals novel SYT1 and DDR2 rearrangements.PLoS One. 2014 Feb 5;9(2):e87113. doi: 10.1371/journal.pone.0087113. eCollection 2014.
20	Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis.BMC Cancer. 2016 Feb 29;16:170. doi: 10.1186/s12885-016-2209-1.
21	Fatty acid synthesis is a therapeutic target in human liposarcoma. Int J Oncol. 2010 May;36(5):1309-14. doi: 10.3892/ijo_00000616.
22	68Ga-Prostate-Specific Membrane Antigen PET/CT: Incidental Finding of a Liposarcoma.Clin Nucl Med. 2019 Feb;44(2):e90-e92. doi: 10.1097/RLU.0000000000002389.
23	Perilipin 1 Expression Differentiates Liposarcoma from Other Types of Soft Tissue Sarcoma.Am J Pathol. 2019 Aug;189(8):1547-1558. doi: 10.1016/j.ajpath.2019.04.017. Epub 2019 May 22.
24	Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities.J Biol Chem. 2004 Nov 19;279(47):48968-75. doi: 10.1074/jbc.M407841200. Epub 2004 Sep 10.
25	Nelfinavir induces liposarcoma apoptosis through inhibition of regulated intramembrane proteolysis of SREBP-1 and ATF6. Clin Cancer Res. 2011 Apr 1;17(7):1796-806. doi: 10.1158/1078-0432.CCR-10-3216. Epub 2011 Feb 25.
26	The RNA-binding protein FUS/TLS undergoes calcium-mediated nuclear egress during excitotoxic stress and is required for GRIA2 mRNA processing.J Biol Chem. 2019 Jun 28;294(26):10194-10210. doi: 10.1074/jbc.RA118.005933. Epub 2019 May 15.
27	miR-193b-Regulated Signaling Networks Serve as Tumor Suppressors in Liposarcoma and Promote Adipogenesis in Adipose-Derived Stem Cells.Cancer Res. 2017 Nov 1;77(21):5728-5740. doi: 10.1158/0008-5472.CAN-16-2253. Epub 2017 Sep 7.
28	G protein pathway suppressor 2 (GPS2) acts as a tumor suppressor in liposarcoma.Tumour Biol. 2016 Oct;37(10):13333-13343. doi: 10.1007/s13277-016-5220-x. Epub 2016 Jul 26.
29	Amplification and overexpression of PRUNE in human sarcomas and breast carcinomas-a possible mechanism for altering the nm23-H1 activity.Oncogene. 2001 Oct 18;20(47):6881-90. doi: 10.1038/sj.onc.1204874.
30	Spindle cell liposarcoma with a TRIO-TERT fusion transcript.Virchows Arch. 2019 Sep;475(3):391-394. doi: 10.1007/s00428-019-02545-5. Epub 2019 Feb 22.
31	Cavin-2 is a specific marker for detection of well-differentiated liposarcoma.Biochem Biophys Res Commun. 2017 Nov 4;493(1):660-665. doi: 10.1016/j.bbrc.2017.08.135. Epub 2017 Sep 1.
32	Identification of Coiled-Coil Domain-Containing Protein 180 and Leucine-Rich Repeat-Containing Protein 4 as Potential Immunohistochemical Markers for Liposarcoma Based on Proteomic Analysis Using Formalin-Fixed, Paraffin-Embedded Tissue.Am J Pathol. 2019 May;189(5):1015-1028. doi: 10.1016/j.ajpath.2019.01.013. Epub 2019 Feb 18.
33	Integrative Genomic Analyses Yield Cell-Cycle Regulatory Programs with Prognostic Value.Mol Cancer Res. 2016 Apr;14(4):332-43. doi: 10.1158/1541-7786.MCR-15-0368. Epub 2016 Feb 8.
34	Epistatic interaction between the lipase-encoding genes Pnpla2 and Lipe causes liposarcoma in mice.PLoS Genet. 2017 May 1;13(5):e1006716. doi: 10.1371/journal.pgen.1006716. eCollection 2017 May.
35	Curcumin and Viscum album Extract Decrease Proliferation and Cell Viability of Soft-Tissue Sarcoma Cells: An In Vitro Analysis of Eight Cell Lines Using Real-Time Monitoring and Colorimetric Assays.Nutr Cancer. 2017 Feb-Mar;69(2):340-351. doi: 10.1080/01635581.2017.1263349. Epub 2017 Jan 3.
36	SBF-1 preferentially inhibits growth of highly malignant human liposarcoma cells.J Pharmacol Sci. 2018 Dec;138(4):271-278. doi: 10.1016/j.jphs.2018.10.009. Epub 2018 Oct 24.
37	The Roles of Sox Family Genes in Sarcoma.Curr Drug Targets. 2016;17(15):1761-1772. doi: 10.2174/1389450117666160502145311.
38	TP53INP2-related basal autophagy is involved in the growth and malignant progression in human liposarcoma cells.Biomed Pharmacother. 2017 Apr;88:562-568. doi: 10.1016/j.biopha.2017.01.110. Epub 2017 Feb 24.
39	DNA damage, somatic aneuploidy, and malignant sarcoma susceptibility in muscular dystrophies.PLoS Genet. 2011 Apr;7(4):e1002042. doi: 10.1371/journal.pgen.1002042. Epub 2011 Apr 14.
40	Focus on the role of Caveolin and Cavin protein families in liposarcoma.Differentiation. 2017 Mar-Apr;94:21-26. doi: 10.1016/j.diff.2016.11.007. Epub 2016 Dec 8.
41	FUS-DDIT3 prevents the development of adipocytic precursors in liposarcoma by repressing PPARgamma and C/EBPalpha and activating eIF4E.PLoS One. 2008 Jul 2;3(7):e2569. doi: 10.1371/journal.pone.0002569.
42	A study of inter-alpha-trypsin inhibitor chains expression in liposarcomas.Eur J Surg Oncol. 2003 Oct;29(8):665-9. doi: 10.1016/s0748-7983(03)00135-5.
43	Evaluation of well-differentiated/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization.Genes Chromosomes Cancer. 2011 Feb;50(2):95-112. doi: 10.1002/gcc.20835.
44	mRNA and protein levels of FUS, EWSR1, and TAF15 are upregulated in liposarcoma.Genes Chromosomes Cancer. 2011 May;50(5):338-47. doi: 10.1002/gcc.20858. Epub 2011 Feb 22.
45	Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma.Cells. 2019 Feb 21;8(2):189. doi: 10.3390/cells8020189.
46	Antiproliferative activity of epigallocatechin?gallate and silibinin on soft tissue sarcoma cells.Mol Med Rep. 2017 Jan;15(1):103-110. doi: 10.3892/mmr.2016.5969. Epub 2016 Nov 28.
47	Hyperexpression of HOXC13, located in the 12q13 chromosomal region, in welldifferentiated and dedifferentiated human liposarcomas.Oncol Rep. 2013 Dec;30(6):2579-86. doi: 10.3892/or.2013.2760. Epub 2013 Oct 1.
48	HMGA2 regulates transcription of the Imp2 gene via an intronic regulatory element in cooperation with nuclear factor-kappaB.Mol Cancer Res. 2007 Apr;5(4):363-72. doi: 10.1158/1541-7786.MCR-06-0331.
49	Nelfinavir inhibits regulated intramembrane proteolysis of sterol regulatory element binding protein-1 and activating transcription factor 6 in castration-resistant prostate cancer.FEBS J. 2012 Jul;279(13):2399-411. doi: 10.1111/j.1742-4658.2012.08619.x. Epub 2012 May 21.
50	MDM2 amplification and loss of heterozygosity at Rb and p53 genes: no simultaneous alterations in the oncogenesis of liposarcomas.J Cancer Res Clin Oncol. 1998;124(10):532-40. doi: 10.1007/s004320050211.
51	Strong smooth muscle differentiation is dependent on myocardin gene amplification in most human retroperitoneal leiomyosarcomas.Cancer Res. 2009 Mar 15;69(6):2269-78. doi: 10.1158/0008-5472.CAN-08-1443. Epub 2009 Mar 10.
52	NAB2, a corepressor of NGFI-A (Egr-1) and Krox20, is induced by proliferative and differentiative stimuli.Mol Cell Biol. 1996 Jul;16(7):3545-53. doi: 10.1128/MCB.16.7.3545.
53	Deletion in human chromosome region 12q13-15 by integration of human papillomavirus DNA in a cervical carcinoma cell line.J Biol Chem. 1995 Oct 13;270(41):24321-6. doi: 10.1074/jbc.270.41.24321.
54	Genomic landscape of liposarcoma.Oncotarget. 2015 Dec 15;6(40):42429-44. doi: 10.18632/oncotarget.6464.
55	Conjugated linoleic acid (CLA) inhibits expression of the Spot 14 (THRSP) and fatty acid synthase genes and impairs the growth of human breast cancer and liposarcoma cells.Nutr Cancer. 2009;61(1):114-22. doi: 10.1080/01635580802348666.
56	Genomic profiling of bone and soft tissue tumors with supernumerary ring chromosomes using tiling resolution bacterial artificial chromosome microarrays.Oncogene. 2006 Nov 9;25(53):7106-16. doi: 10.1038/sj.onc.1209693. Epub 2006 May 29.
57	Translin binds to the sequences adjacent to the breakpoints of the TLS and CHOP genes in liposarcomas with translocation t(12;6).Oncogene. 2000 Nov 23;19(50):5821-5. doi: 10.1038/sj.onc.1203943.